RESUMO
CONTEXT: Breast cancer is a heterogeneous disease with several histological subtypes. Its prognosis and management are influenced by human epidermal growth factor receptor type 2 (HER2/neu) expression. Varying grades of HER2/neu overexpression are likely to have different morphological features. Digital breast tomosynthesis (DBT) enhances lesion visibility and hence that it may reveal features closer to histomorphological findings. AIMS: The aim of this study is to correlate digital mammography (DM) and DBT findings of self-detected tumors with HER2/neu status, to determine whether differences in imaging features can help predict the degrees of HER2/neu overexpression. SETTINGS AND DESIGN: Prospective study conducted in a tertiary care hospital. METHODS: For 100 consecutive patients with self-detected lumps, DM and DBT data were reviewed by two radiologists who were blinded to histopathology. Of these, 63 patients with histologically proven breast cancer were recruited and their DM and DBT findings compared and correlated with HER2neu status (scores 0-3+). STATISTICAL ANALYSIS: Pearson's Chi-squared test and Fisher's exact test were used (SPSS version 22.0, IBM). RESULTS: Morphology of lesions at both DM and DBT varied with HER2/neu status (P = 0.04 and 0.015, respectively). HER2-0 tumors mostly presented as masses without microcalcifications (88.8%), while most of HER2-3+ tumors as masses or asymmetries with microcalcifications (61.9%). The presence or absence of calcifications varied significantly with HER2/neu status. Breast imaging-reporting and data system (BI-RADS) scoring varied significantly (P < 0.001) with higher HER2 signal, more frequently associated with BI-RADS 5 score. CONCLUSION: DM and DBT features vary with the intensity of HER2 immunostaining. Higher BI-RADS scores, microcalcifications, and spiculated margins are frequently associated with HER2/neu 3+ lesions.
RESUMO
Scarless (in the neck) endoscopic thyroidectomy (SET) has evolved into a cosmetically preferred alternative to conventional thyroidectomy (ConT). Recently many of our patients are demanding SET; however their goitres are larger than the recommended size of 4-6 cm. Our aim was to compare the outcomes of ET for small (<6 cm) vs large (≥6 cm) goitres and determine its feasibility in such cases. This is a retrospective analysis of prospectively maintained database of patients undergoing ET. Patients were divided into 2 groups: I, small (<6 cm) and II, large goitres (≥6 cm). Their demographic and clinicopathological profiles, operation time, conversion and complication rates, and hospital stay were compared. 99 patients (101 procedures) were included: group I, 60 patients (61 procedures), and group II, 39 patients (40 procedures). Mean tumor size (± SD) was 4.4 ± 0.9 cm and 6.7 ± 1.1 cm in groups I and II, respectively. The groups were comparable with respect to demographic and clinical profile except for mean duration of goiter [30.1 ± 32.6 months (group I) vs 60.5 ± 102.4 months (group I), p = 0.03] and gland weight [21.5 ± 15.3 grams (group I) vs 62.3 ± 51.3 grams (group II), p = 0.001]. Although there was no significant difference between mean operating times, long term perioperative outcomes, and conversion rates, temporary hypocalcaemia and length of stay were longer in group II. One patient had permanent vocal cord palsy (~1%, 1/101); none had permanent hypoparathyroidism. Our results indicate that ET can be offered to a subset of patients with larger goitres desirous of SET with no significant difference in mean operation time, conversions, and long term postoperative complications in experienced hands.
RESUMO
INTRODUCTION: In India and other developing countries, breast conservation surgery (BCS) rates in breast cancer patients are low due to advanced disease at presentation and misconceptions about BCS outcomes. Many patients presenting with large or locally advanced breast cancers (LABC) can be offered post-neoadjuvant chemotherapy (NACT) BCS, safety of which is not as well established as that of primary BCS. This retrospective study compared pathological and surgical outcome parameters in patients undergoing primary and post-NACT BCS. METHODS: All non-metastatic breast cancer patients undergoing BCS during 2011-2015 with 1-year follow-up were included. Outcome parameters in form of margin infiltration, ipsilateral breast tumor recurrence (IBTR) rates and IBTR-free survival were compared between primary and post-NACT BCS patients groups. RESULTS: One hundred and twenty-nine patients underwent BCS; 95 underwent primary and 34 post-NACT BCS. Patients in both groups underwent similar multimodality treatment as per institutional protocols. Post-NACT patients more frequently required oncoplastic volume displacement or replacement surgery (p = 0.002). Re-excision of infiltrated margins was needed more frequently in primary BCS compared with post-NACT BCS group (14.4 vs. 8.8%; p = 0.40). IBTR (Mean follow-up = 30.7 months) was seen in 8.8% post-NACT patients compared with 2.1% primary BCS (p = 0.114). IBTR-free survival did not differ significantly between the groups in stage-wise comparison. CONCLUSION: Post-NACT BCS is safe even in large tumors and LABC, though many require oncoplastic procedures for satisfactory cosmesis. In a developing country where many patients present with large breast cancers or LABC, the benefits of BCS can be offered to a majority with the help of NACT, without compromising the chances of cure.